Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Jeanette K. Doorduijn*, Gustaaf W. van Imhoff, Bronno van der Holt, Harry C. Schouten, Martijn R. Schaafsma, Marius A. MacKenzie, Joke W. Baars, Marie Jose Kersten, Pieternella J. Lugtenburg, Martin J. van den Bent, Roelien H. Enting, Fokje M. Spoelstra, Philip Poortmans, Jacoline E. C. Bromberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)497-503
Number of pages7
JournalHematological Oncology
Volume35
Issue number4
DOIs
Publication statusPublished - Dec 2017

Keywords

  • clinical trial
  • methotrexate
  • rituximab
  • secondary CNS lymphoma
  • transplantation
  • treatment
  • NON-HODGKINS-LYMPHOMA
  • PRIMARY CNS LYMPHOMA
  • MABTHERA INTERNATIONAL TRIAL
  • CHEMOTHERAPY PLUS RITUXIMAB
  • STUDY-GROUP DSHNHL
  • AGGRESSIVE LYMPHOMA
  • ELDERLY-PATIENTS
  • MARROW-TRANSPLANTATION
  • INTRAOCULAR LYMPHOMA
  • RESPONSE CRITERIA

Cite this

Doorduijn, J. K., van Imhoff, G. W., van der Holt, B., Schouten, H. C., Schaafsma, M. R., MacKenzie, M. A., Baars, J. W., Kersten, M. J., Lugtenburg, P. J., van den Bent, M. J., Enting, R. H., Spoelstra, F. M., Poortmans, P., & Bromberg, J. E. C. (2017). Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology, 35(4), 497-503. https://doi.org/10.1002/hon.2342